### Consensus provenance reconciliation — 9 October 2026

Case-specific Consensus discovery records were located and linked to this final edition. This supplements the review's provenance; it leaves the original assessed claim, grades and source counts intact. Provider summaries and full-text badges do not establish examination of original primary passages by this reviewer. Source access and incorporation retain the limits stated in the original methods and any dated research update.

Recorded evidence artifacts:

- `deliverables/prepublication-enrichment-2026-10-05/website-series/mdd-serotonin/consensus-browser-links.json`
- `deliverables/prepublication-enrichment-2026-10-05/website-series/mdd-serotonin/consensus-browser.txt`
- `deliverables/prepublication-enrichment-2026-10-05/website-series/mdd-serotonin/consensus-targeted-check.txt`

The located artifacts do not state a reliable source-comparison count. No count is inferred.

**Existing source reconciliation:** Yes; 7 distinct primary identifiers, abstract/metadata checks documented; excludes unrelated PMID from verification. No independently readable body verified; update explicitly avoids padding with meta-analyses.

Matched primary identifiers in the preserved dated ledger: PMID 2184795, PMID 7944875, PMID 12869766, PMID 15289275, PMID 19755572, PMID 30845820, PMID 36635177. These are historical checks, not newly credited complete-paper examinations.

Shared template wording about an amyloid-specific Deep follow-up is not credited as a case-specific run for this topic. The actual raw case records above establish provider use.

No earlier adversarial approval has been verified for this edition at the supplement date. This provenance supplement has no separate approval and is not an independent or blinded adjudication. No score or confidence change is made by this reconciliation.